Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study

被引：0
|
作者：
Andreas Straube
Gregor Broessner
Charly Gaul
Xenia Hamann
Joachim Hipp
Torsten Kraya
Lars Neeb
机构：
[1] University Hospital,Department of Neurology
[2] LMU Munich,Department of Neurology
[3] Innsbruck Medical University,Department of Neurology
[4] Headache Center Frankfurt,Department of Neurology
[5] Teva GmbH,Department of Neurology
[6] Hospital Sankt Georg Leipzig gGmbH,undefined
[7] Headache Center Halle,undefined
[8] University Hospital Halle,undefined
[9] Helios Global Health,undefined
[10] Charité-Universitätsmedizin Berlin,undefined
来源：
The Journal of Headache and Pain | / 24卷
关键词：
Fremanezumab; Calcitonin gene-related peptide; Migraine; Non-responder;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] THE IMPACT OF USING REAL-WORLD DATA ON THE COST-EFFECTIVENESS OF FREMANEZUMAB FOR MIGRAINE PREVENTION IN A UK HEALTHCARE PERSPECTIVE ANALYSIS
    Sacco, S.
    Freddi, M.
    Edwards, J.
    Akcicek, H.
    Driessen, M.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S118 - S118
  • [32] Two year outcome of fremanezumab in refractory chronic migraine patients: Real-world data from the Hull Migraine Clinic, UK
    Khan, Rafiullah
    Nasergivehchi, Somayeh
    Khalil, Modar
    Delroasario, Helen
    Ahmed, Fayyaz
    [J]. CEPHALALGIA, 2023, 43 (1supp) : 269 - 270
  • [33] One year outcome of fremanezumab in refractory chronic migraine patients: Real-world data from the Hull Migraine Clinic, UK
    Nasergivehchi, Somayeh
    Cheng, Fan
    Hussain, Mariam
    Khalil, Modar
    Ahmed, Fayyaz
    [J]. CEPHALALGIA, 2022, 42 (1_SUPPL) : 130 - 130
  • [34] Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study
    Ashina, Messoud
    Mitsikostas, Dimos D.
    Amin, Faisal Mohammad
    Kokturk, Pinar
    Schankin, Christoph J.
    Sahin, Gurdal
    Pozo-Rosich, Patricia
    Dorman, Paul J.
    Nezadal, Tomas
    Poole, Anne Christine
    Martins, Isabel Pavao
    Sumelahti, Marja-Liisa
    Campos, Verena Ramirez
    Ahn, Andrew H.
    Lyras, Leonidas
    Tassorelli, Cristina
    [J]. CEPHALALGIA, 2023, 43 (11)
  • [35] REAL-WORLD CLINICAL CHARACTERISTICS OF PATIENTS WITH MIGRAINE WHO INITIATED FREMANEZUMAB IN SWEDEN: AN OBSERVATIONAL, NATIONWIDE REGISTERBASED STUDY
    Linde, M.
    Driessen, M.
    Akcicek, H.
    Blomstrand, F.
    Fast, T.
    Haas, J.
    Krasenbaum, L. J.
    Seidel, K.
    Vasilevska, M.
    Ernstsson, O.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S493 - S493
  • [36] Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study
    Overeem, Lucas Hendrik
    Lange, Kristin Sophie
    Fitzek, Mira Pauline
    Siebert, Anke
    Steinicke, Maureen
    Triller, Paul
    Hong, Ja Bin
    Reuter, Uwe
    Raffaelli, Bianca
    [J]. FRONTIERS IN NEUROLOGY, 2023, 14
  • [37] Menopause and its impact on the effectiveness of fremanezumab for migraine prophylaxis: post-hoc analysis of a prospective, real-world Greek registry
    Argyriou, Andreas A.
    Dermitzakis, Emmanouil V.
    Xiromerisiou, Georgia
    Rikos, Dimitrios
    Rallis, Dimitrios
    Soldatos, Panagiotis
    Litsardopoulos, Pantelis
    Andreou, Anna P.
    Vikelis, Michail
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2024,
  • [38] Effectiveness and tolerability of eptinezumab in treating patients with migraine resistant to conventional preventive medications and CGRP (receptor) antibodies: a multicentre retrospective real-world analysis from Germany
    Scheffler, Armin
    Wenzel, Pauline
    Bendig, Merle
    Gendolla, Astrid
    Basten, Jale
    Kleinschnitz, Christoph
    Nsaka, Michael
    Lindner, Diana
    Naegel, Steffen
    Burow, Philipp
    Fleischmann, Robert
    Holle, Dagny
    [J]. JOURNAL OF HEADACHE AND PAIN, 2024, 25 (01):
  • [39] Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or CGRP mAbs: A retrospective claims analysis study
    Schwedt, T. J.
    Lee, J.
    Knievel, K.
    McVige, J. W.
    Wang, W.
    Wu, Z.
    Gillard, P.
    Shah, D.
    Blumenfeld, A. M.
    [J]. HEADACHE, 2022, 62 : 81 - 82
  • [40] Real-World Persistence and Costs Among Patients With Chronic Migraine Treated With OnabotulinumtoxinA or CGRP mAbs: A Retrospective Claims Analysis Study
    Schwedt, Todd J.
    Lee, Jae
    Knievel, Kerry
    McVige, Jennifer
    Wang, Weiying
    Wu, Zheng
    Gillard, Patrick
    Shah, Darshini
    Blumenfeld, Andrew M.
    [J]. CEPHALALGIA, 2022, 42 (1_SUPPL) : 18 - 19
12345